Site Map
Posts
- Category: Wp Feeds (continued)
- AACR: Research, $$ Needed or Cancer Will Be Top Killer
- AAN: Don't Stop Warfarin for Dental Visits (CME/CE)
- AAP Releases New C. Diff Guidance (CME/CE)
- AAP Releases New C. Diff Guidance (CME/CE)
- AAP Updates Vaccine Recommendations (CME/CE)
- AAP: Give Healthy Infants Hep B Vax Soon After Birth
- AAP: Not All Infant Reflux Is Disease (CME/CE)
- AAP: Urinary Stones in Kids on the Rise (CME/CE)
- AASLD Liver Meeting Covers a Lot of Ground
- AASLD: African Americans Face Hep C 'Triple Whammy' (CME/CE)
- AASLD: Alcohol Not Main Killer of Older Drinkers (CME/CE)
- AASLD: Alcohol Not Main Killer of Older Drinkers (CME/CE)
- AASLD: Anti-HCV Drug Boosts Response Rates (CME/CE)
- AASLD: Antibiotic Reverses Cognition Loss in MHE (CME/CE, with video)
- AASLD: Antiviral Likely Too Costly for Initial HCV Tx (CME/CE, with video)
- AASLD: Cirrhosis Patients Benefit from Anticoagulant (CME/CE)
- AASLD: Drug for Autoimmune Liver Disease Promising (CME/CE)
- AASLD: Drug Therapy Okay for Pregnant Women With Hep B (CME/CE)
- AASLD: Early Study Shows HCV Vaccine Works (CME/CE)
- AASLD: Fatty Liver May Benefit from Mediterranean Diet (CME/CE)
- AASLD: Focus on Liver Broadens
- AASLD: HBV New Target for HIV Drug (CME/CE)
- AASLD: HCV 'Cure' Now on Agenda (with video)
- AASLD: HCV Drug Effective in Patients Co-Infected with HIV (CME/CE)
- AASLD: HCV Phone Program Equals Office Visits (CME/CE)
- AASLD: HCV Testing by Birth Cohort Cost-Effective (CME/CE)
- AASLD: Hepatitis C Now Bigger Killer than HIV (CME/CE)
- AASLD: Hepatitis E Rare After Heart Transplant (CME/CE)
- AASLD: High-Risk HPV Seen in Low-Risk Liver Tx Patients (CME/CE)
- AASLD: Human Cells Grow on Animal Liver Scaffolds (CME/CE)
- AASLD: Livers from Older Donors Okay for Transplant (CME/CE)
- AASLD: Long-Term Outcomes Better With SVR (CME/CE)
- AASLD: Many Liver Recipients Fare Well 20 Years Out (CME/CE, with video)
- AASLD: Men Make Better Liver Donors (CME/CE)
- AASLD: MicroRNA Drug Safe in Ongoing HCV Study (CME/CE)
- AASLD: Milk Thistle No Help in Chronic HCV (CME/CE)
- AASLD: New Diabetes Meds Diminish Markers of Fatty Liver (CME/CE)
- AASLD: New HCV Drug Promising, Cuts Out Interferon (CME/CE)
- AASLD: New HCV Drug Promising, Cuts Out Interferon (CME/CE)
- AASLD: New HCV Drug Speeds Viral Clearance (CME/CE)
- AASLD: New HCV Drugs Draw Attention (with video)
- AASLD: New PI Effective, Safe in HCV Trial (CME/CE)
- AASLD: Oral HCV Combo Yields Rapid Response (CME/CE)
- AASLD: Platelet Booster Aids HCV Therapy (CME/CE)
- AASLD: Rapid Response for Once-Daily Protease Inhibitor (CME/CE)
- AASLD: Six Months of Novel Agent Works in Hep C (CME/CE)
- AASLD: Successful HCV Tx Cuts Deaths Post-Transplant (CME/CE)
- AASLD: Two New HCV Drugs Need Old Hands' Help (CME/CE)
- AASLD: Virus Shuts Down Liver Cancer in Early Trials (CME/CE)
- AASLD: Vitamin E Resolves NASH in Children (CME/CE, with video)
